Ligand Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: LGNDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ligand Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Ligand Pharmaceuticals generated $24.0 million of operating cash flow and spent $26,000 on capital expenditures. That left free cash flow of $24.0 million, a free-cash-flow margin of 37.7% of revenue. Free cash flow was up 53.9% from the prior year's $15.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Ligand Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 48.51M | -13.35M | 44.78M | 117.27M | 4.85M | -42.45M | -31.09M | -7.17M | -51.91M | 86.14M | 18.19M | -10.27M |
| Net Income growth (YoY) | +900.78% | — | — | — | — | -149.28% | -270.93% | — | -2366.86% | +105.34% | — | -2642.82% |
| Depreciation & Amortization | 8.21M | 8.22M | 8.21M | 8.27M | 8.52M | 8.77M | 8.63M | 8.99M | 8.85M | 8.77M | 8.92M | 8.61M |
| Stock-Based Compensation | 13.65M | 10.60M | 14.27M | 14.75M | 10.00M | 7.84M | 7.52M | 15.17M | 11.06M | 7.33M | 5.72M | 6.88M |
| Change in Working Capital | -7.60M | 4.98M | 8.03M | -11.63M | -4.33M | -3.52M | 8.05M | 8.72M | -5.19M | 4.17M | 6.49M | -10.79M |
| Operating Cash Flow | 24.02M | 48.69M | 45.91M | 13.09M | 15.80M | -25.45M | 28.47M | 36.53M | 13.31M | 18.73M | 8.06M | 7.65M |
| Capital Expenditures | -26.00K | -228.00K | -9.00K | -15.00K | -214.00K | -214.00K | -712.00K | -596.00K | -408.00K | -105.00K | -417.00K | -487.00K |
| Investing Cash Flow | 321.12M | -94.35M | -18.10M | -353.44M | -10.67M | 4.89M | -38.62M | -46.51M | -54.76M | -3.77M | -10.28M | -19.50M |
| Share Repurchases | — | — | 0 | -15.00M | — | — | 0 | — | — | — | — | — |
| Debt Repaid | — | — | — | — | — | — | 0 | 0 | — | — | 0 | 0 |
| Financing Cash Flow | 546.43M | -14.13M | 8.33M | 409.64M | 14.99M | -4.75M | 20.39M | 55.08M | 9.49M | 12.18M | 5.32M | 3.27M |
| Net Change in Cash | 891.61M | -59.83M | — | — | 19.68M | -24.32M | 8.69M | 45.48M | -31.95M | 27.14M | 3.10M | -8.59M |
| Free Cash Flow | 23.99M | 48.46M | 45.91M | 13.07M | 15.59M | -25.66M | 27.76M | 35.93M | 12.91M | 18.63M | 7.65M | 7.16M |
This table shows 12 quarterly periods of Ligand Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LGND's reporting calendar. What is a cash flow statement?